Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/15/2007US20070264336 Hydrophilic/lipophilic polymeric matrix dosage formulation
11/15/2007US20070264335 Modified release tablets comprising tramadol
11/15/2007US20070264334 Modified release formulation of fenofibric acid in a hydroxypropyl methylcellulose matrix; in vitro dissolution is substantially independent of the dissolution media ionic strength
11/15/2007US20070264333 Method of treatment
11/15/2007US20070264332 Sustained Release Pharmaceutical Formulation
11/15/2007US20070264331 Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin
11/15/2007US20070264329 Calcium compositions
11/15/2007US20070264327 Analgesically effective amount of opioid analgesic is combined with gel forming polymer to form a matrix, a surfactant to cause mucosal tissue irritation, and an emetic to cause emesis if greater than a prescribed amount of the analgesic included
11/15/2007US20070264325 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
11/15/2007US20070264324 Use of Vegetable Anthraquinone Derivatives and Vegetable Polysaccharides For Treating Human Immunodeficiency Virus (HIV)
11/15/2007US20070264323 Controlled dose drug delivery system
11/15/2007US20070264322 Method for making liposomes conjugated with temperature-sensitive ligands
11/15/2007US20070264321 Method of treating skin wounds with vectors encoding hepatocyte growth factor
11/15/2007US20070264320 Microfluidic device for forming monodisperse lipoplexes
11/15/2007US20070264319 Transdermal Antiemesis Delivery System, Method and Composition Therefor
11/15/2007US20070264318 Compositions for the treatment and prevention of eyelid swelling
11/15/2007US20070264317 Imiquimod cream formulation
11/15/2007US20070264313 Methods and compositions relating to animal dietary acids
11/15/2007US20070264309 Method Of Treating Atrophic Vaginitis
11/15/2007US20070264304 Provision of vascular grafts with an active principle
11/15/2007US20070264302 Immobilized biologically active entities having high biological activity following mechanical manipulation
11/15/2007US20070264301 Medical device; substrate with polymeric covering; binding to anti-thrombin III compound
11/15/2007US20070264299 contain 3-bromo-1-(3-chloro-2-pyridinyl)-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-pyrazole-5-carboxamide; for controlling invertebrate pests in both agronomic and nonagronomic environments
11/15/2007US20070264296 Biofilm extracellular polysachharide solvating system
11/15/2007US20070264289 Compositions and methods of administering doxepin to mucosal tissue
11/15/2007US20070264285 Compositions Comprising Cationic Microparticles And Hcv B1e2 Dna And Methods Of Use Thereof
11/15/2007US20070264283 Vaccine
11/15/2007US20070264282 Herpes virus strains for gene therapy
11/15/2007US20070264273 Sphingoid polyalklamine conjugates, isomers and uses thereof
11/15/2007US20070264271 Potent Immunostimulatory from Microalgae
11/15/2007US20070264262 Adrenoceptor beta 2-mediated diseases such as asthma and chronic obstructive pulmonary disease (COPD); N-(4-tert-butylbenzyl)-4-{[({3-[(2R)-2-(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl}amino)propyl]phenyl}acetyl)amino]methy} benzamide
11/15/2007US20070264252 Modulators of Ms4a Gene Products
11/15/2007US20070264246 ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2beta
11/15/2007US20070264245 Compositions and minimally invasive methods for treating incomplete tissue repair
11/15/2007US20070264241 Compounds for Enhanced Cancer Therapy
11/15/2007US20070264235 Polypeptide Having an Improved Cytosine Deaminase Activity
11/15/2007US20070264234 Cytokine Variant Polypeptides
11/15/2007US20070264230 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
11/15/2007US20070264227 Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration
11/15/2007US20070264225 Hindered Amine Nitric Oxide Donating Polymers for Coating Medical Devices
11/15/2007US20070264224 Exfoliating and Softening Composition
11/15/2007US20070264223 Use of hydrophilic-rich alkylmethylsiloxane-dimethylsiloxane-polyoxyalkylene copolymers as emulsifiers for the preparation of cosmetic o/w emulsions of improved aesthetic properties and mildness
11/15/2007US20070264222 Enhanced protection against skin injury in humans
11/15/2007US20070264211 Composition Comprising Sodium Silicate for Use in the Treatment of Dry Skin Conditions
11/15/2007US20070264210 Method of enhancing penetration of water-soluble actives
11/15/2007US20070264209 Soluble containers for self-tanning formulations
11/15/2007US20070264208 Cosmetic and/or pharmaceutical composition comprising at least one copolymer comprising at least one ionizable group, and cosmetic treatment process
11/15/2007US20070264206 Mucosal formulation
11/15/2007US20070264205 reducing the formation of cellulite in skin by topically applying to the skin a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate
11/15/2007US20070264202 Pharmaceutical Composition Comprising an Isomer of Betamimetic Agent and an Anti-Cholinergic Agent
11/15/2007US20070264198 Tumor necrosis agent
11/15/2007US20070264197 Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
11/15/2007US20070264196 Modulators of ATP-binding cassette transporters
11/15/2007US20070264195 Modulation of Activity of Neurotrophins
11/15/2007US20070264194 Peptides That Bind To Atherosclerotic Lesions
11/15/2007US20070261695 Sublingual fentanyl spray
11/15/2007DE202004021381U1 Salz einer Sulfonsäure mit Clopidogrel und dessen Verwendung zur Herstellung pharmazeutischer Formulierungen Salt of a sulfonic acid with clopidogrel and its use for the preparation of pharmaceutical formulations
11/15/2007DE19544507B4 Cyclosporin enthaltende Präparate Cyclosporin-containing preparations
11/15/2007DE112005003227T5 Neues Verfahren zur Herstellung von Pramipexol und dem Gemisch seiner optischen Isomeren durch Reduktion mit Natriumtriacetoxyborhydrid New process for the production of pramipexole and the mixture of its optical isomers by reduction with sodium triacetoxyborohydride
11/15/2007DE10362135B4 Composition for treating fish infections comprises polyethylene glycol and a water-insoluble active ingredient
11/15/2007DE102007017298A1 New nanoparticles containing nicotine and/or cotinine useful e.g. for cigarette weaning and to treat e.g. attention-deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease and Binswanger's disease
11/15/2007DE102006046922B3 Biofilm-hemmende Wirkung sowie anti-infektive Aktivität N,C-verknüpfter Arylisochinoline, deren pharmazeutischen Zusammensetzung und deren Verwendung Biofilm-inhibitory effect and anti-infective activity of N, C-linked Arylisochinoline whose pharmaceutical composition and the use thereof
11/15/2007DE102006021878A1 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Phenylamino-benzoxazole substituted carboxylic acids, process for their preparation and their use as medicaments
11/15/2007DE102006020582A1 Verfahren zur Herstellung einer triterpensäurehaltigen wässrigen Lösung, triterpensäurehaltige wässrige Lösung und deren Verwendung A process for the preparation of a triterpenic acid aqueous solution containing triterpenic acid aqueous solution and the use thereof
11/15/2007CA2846817A1 Short interfering ribonucleic acid (sirna) for oral administration
11/15/2007CA2846756A1 Short interfering ribonucleic acid (sirna) for oral administration
11/15/2007CA2846732A1 Short interfering ribonucleic acid (sirna) for oral administration
11/15/2007CA2833705A1 Use of dpp iv inhibitors
11/15/2007CA2810295A1 Polymorphs
11/15/2007CA2682385A1 Treating cancer with cardiac glycosides
11/15/2007CA2661818A1 Acute pain medications based on fast acting diclofenac-opioid combinations
11/15/2007CA2657956A1 Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
11/15/2007CA2656780A1 Anti-viral pyrimidine nucleoside derivatives
11/15/2007CA2654540A1 Histone deacetylase and tubulin deacetylase inhibitors
11/15/2007CA2652215A1 Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
11/15/2007CA2651696A1 Modified release tablets comprising tramadol
11/15/2007CA2651691A1 Glutaminase and 6-diazo-5-oxo-l-norleucine (don) for cancer therapy
11/15/2007CA2651596A1 Percutaneous absorption preparations of antidementia drugs
11/15/2007CA2651580A1 The use of nicotine, nicotines analogues, precursors or derivatives in the treatment of various pathological processes
11/15/2007CA2651558A1 Novel compounds
11/15/2007CA2651557A1 17-oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies
11/15/2007CA2651556A1 3-tetrazolylindazoles and 3-tetrazolylpyrazolopyridines and their use
11/15/2007CA2651385A1 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
11/15/2007CA2651317A1 Compositions and methods for detecting and treating hiv infection
11/15/2007CA2651303A1 Factor xa inhibitors
11/15/2007CA2651300A1 A sustained-release intraocular implant comprising a vasoactive agent
11/15/2007CA2651232A1 Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350
11/15/2007CA2651226A1 Pentacyclic indole derivatives as antiviral agents
11/15/2007CA2651225A1 Novel drugs for anti-herpes virus treatments
11/15/2007CA2651216A1 Aptamers directed to muc1
11/15/2007CA2651206A1 Bivalent smac mimetics and the uses thereof
11/15/2007CA2651201A1 Use of a compound with rankl activity
11/15/2007CA2651197A1 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer
11/15/2007CA2651152A1 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
11/15/2007CA2651138A1 Pharmaceutical composition
11/15/2007CA2651128A1 Benzimidazole modulators of vr1
11/15/2007CA2651089A1 Polymorphs
11/15/2007CA2651045A1 Therapeutic cyclopentane derivatives
11/15/2007CA2651033A1 Constrained compounds as cgrp-receptor antagonists
11/15/2007CA2651022A1 12-aryl or heteroaryl prostaglandin analogs
1 ... 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 ... 7860